PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Negative EBIT growth while GNPX is at 35.72%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-30.79%
Negative operating income growth while GNPX is at 35.72%. Joel Greenblatt would press for urgent turnaround measures.
-31.28%
Negative net income growth while GNPX stands at 35.71%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-21.00%
Negative EPS growth while GNPX is at 36.54%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.22%
Negative diluted EPS growth while GNPX is at 36.58%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.78%
Share count expansion well above GNPX's 1.28%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.68%
Diluted share count expanding well above GNPX's 1.34%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-4.24%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7210.53%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
76.96%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
70.68%
Positive 3Y OCF/share CAGR while GNPX is negative. John Neff might see a big short-term edge in operational efficiency.
-11609.25%
Negative 10Y net income/share CAGR while GNPX is at 55.72%. Joel Greenblatt sees a major red flag in long-term profit erosion.
81.05%
5Y net income/share CAGR 1.25-1.5x GNPX's 55.72%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
70.82%
3Y net income/share CAGR 1.25-1.5x GNPX's 55.72%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
881.79%
Equity/share CAGR of 881.79% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-26.92%
Negative 5Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-79.64%
Negative 3Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-41.29%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-11.75%
We’re deleveraging while GNPX stands at 1.17%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
20.45%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
69.30%
We expand SG&A while GNPX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.